ReviewFrontiers in immunology2026
RNA-binding protein RBM47 in health and disease: molecular mechanisms, preclinical evidence, and translational challenges.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
RNA-binding motif protein 47 (RBM47) is an evolutionarily conserved multifunctional RNA-binding protein. It mediates post-transcriptional regulation through C-to-U RNA editing, alternative splicing, and messenger RNA (mRNA) stability control. Preclinical evidence indicates that RBM47 exhibits context-dependent, dual effects in human disease. In breast cancer (BC), colorectal cancer (CRC), renal cell carcinoma (RCC), papillary thyroid carcinoma (PTC), and non-small cell lung cancer (NSCLC), experimental studies suggest that RBM47 exerts tumor-suppressive activity through the inhibition of the Wnt/β-catenin, phosphoinositide 3-kinase (PI3K)-AKT, and nuclear factor erythroid 2-related factor 2 (Nrf2) pathways. Conversely, in glioma and pancreatic cancer (PC), cell and animal models indicate that RBM47 exerts oncogenic activity by promoting M2 macrophage polarization and immune evasion. Furthermore, aberrant RBM47 expression has been implicated in postoperative cognitive dysfunction (POCD), inflammatory bowel disease (IBD), and antiviral innate immune regulation in preclinical models. This review summarizes the molecular characteristics and pathological mechanisms of RBM47, discusses the preclinical rationale for its potential utility as a biomarker and therapeutic node, and critically analyzes current research limitations, conflicting evidence, and translational bottlenecks. All biomarker and therapeutic applications discussed remain at the preclinical or retrospective-correlative stage; no RBM47-targeted intervention has entered clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.